After a sustained effort in support of National Institutes of Health (NIH) funding by the American Society of Nephrology (ASN) and the broader kidney community, Congress passed a $2 billion funding increase for NIH for fiscal year (FY) 2019. Additionally, the National Institute of Diabetes and Digestive Kidney Diseases (NIDDK) received a 5% increase that was widely celebrated by the kidney community.
Unfortunately, the gains seen by NIH and NIDDK have not translated into funding for the Division of Kidney, Urologic, & Hematologic Diseases (KUH), which saw a 2% decrease in total funding. NIDDK is a payline-driven funding program that
KidneyX, a public-private partnership between the US Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN), aims to accelerate innovation in the prevention, diagnosis, and treatment of kidney diseases.
To introduce new voices and perspectives to the kidney space and seek to improve collaboration and communication across the nephrology community, KidneyX hosted its inaugural Summit on April 29–30, 2019, in Washington, DC. The 2019 KidneyX Summit brought together insights from a variety of fields outside of the traditional nephrology community and encouraged investment partnerships for innovative solutions to improve kidney care. The summit included panel
On May 22, 2019, the White House released its Unified Spring Agenda outlining the issues the administration will address through a proposed rule process in the coming months. The agenda highlighted administration priorities of improving the data used to evaluate Organ Procurement Organizations (OPOs) and removing financial barriers to living donation. Both policy priorities were discussed when ASN met with Department of Health and Human Services (HHS) Secretary Alex Azar and other senior administration officials in February to urge the department to address these issues.
The administration will address transplantation through two upcoming rules by:
On January 20, 2021, Joseph R. Biden Jr. and Kamala D. Harris were sworn in as President and Vice President of the United States. Their ascension to the White House, amid the twin public health crises posed by the COVID-19 pandemic and system racism, provides new opportunities for the kidney community to collaborate and advance polices that will benefit people with kidney diseases and their families.
The Biden-Harris ticket campaigned on the need for the country to build back better, and the nation owes it to the 37 million Americans living with kidney diseases, especially those from communities of color
There have been concerns for years that the National Institutes of Health (NIH) has limited resources for too many researchers applying for grant funding. This situation has created a competitive environment as applications go unfunded, which is particularly challenging for many new- and mid-career investigators to navigate. In passing the 21st Century Cures Act, Congress gave NIH an edict to promote policies that support early-career investigators. To that end, NIH announced a major policy change in May 2017 titled the Grant Support Index (GSI) that aimed to cap the number of research grants an investigator may hold.
The Department of Veterans Affairs (VA) Center for Innovation (VACI), the innovation hub within the department, recently released a Broad Agency Announcement (BAA). The announcement seeks to source and fund early stage research, development, prototyping, and piloting of innovative ideas in the kidney space.
VA BAAs are competitive procedures in which proposals from outside groups are solicited and contracts are awarded for research and development.
One in 6 veterans have chronic kidney disease and more than 13,000 veterans experience kidney failure each year, according to the VA’s announcement. To address the need for innovation in kidney disease prevention, care coordination,
The All of Us Research Program, an element of the National Institutes of Health’s (NIH) Precision Medicine Initiative (PMI), will allow researchers, health care providers, and patients to work together and develop individualized care. In a truly historic effort, the All of Us Research Program aims to collect data from more than 1 million people to accelerate health research and medical innovation through precision medicine. This project is a network of US industry and universities that seeks to generate new knowledge on the biological, environmental, and behavioral influences on diseases with the goal of developing more
In addition to the “proposed” sweeping reduction to the National Institutes of Health (NIH) budget, which is not expected to be supported by Congress, President Trump’s fiscal year 2018 budget includes significant reductions to NIH support for costs associated with conducting federally supported research, causing concern within the medical research community.
The total cost of federally sponsored research includes both direct and facilities and administrative (F&A) expenses (previously referred to as “indirect costs”). Direct costs are used to cover portions of researcher salaries and necessary equipment and supplies, while F&A costs refer to necessary research infrastructure and operating expenses that
The National Institutes of Health (NIH) announced the national enrollment date for its All of Us Research Program, a groundbreaking scientific effort to gather data from one million individuals living in the United States. This program will accelerate research by producing new knowledge with the goal of developing personalized and highly effective health care to treat diseases. In preparation for its national launch, the program enrolled 25,000 participants as part of its year-long beta testing phase. Enrollment will be open to people ages 18 and older, regardless of health status, with plans for future phases of the program to include children.
The National Institutes of Health’s (NIH) All of Us Research Program is collecting data from more than one million people to accelerate health research and medical innovation through precision medicine. This historic project aims to generate new knowledge with the goal of developing more effective therapies to treat diseases by leveraging the statistical power of a cohort of this size.